$MNOV News

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

MediciNova to Participate at the 38th Annual ROTH Conference

HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10

MediciNova: Q4 Earnings Snapshot

D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study

2026 New Year’s Greetings from the CEO

MediciNova Entered $50M Equity Distribution Agreement With Lucid Capital Markets On Dec 29

MediciNova Entered $50M Equity Distribution Agreement With Lucid Capital Markets On Dec 29

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage

Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

MediciNova Details COMBAT-ALS Baseline Characteristics, With Mean Age 60.6 And Mean Disease Duration 12.5 Months In 234 Randomized ALS Patients

Message from the CEO to MediciNova Shareholders